Propanc Biopharma Provides Shareholder Update and Plans to Enter Clinical Development Stage with Lead Cancer Treatment Candidate

Propanc Biopharma, a biopharmaceutical company focused on developing novel cancer treatments for patients with recurring and metastatic cancer, has announced that it is entering into a transformational stage as it prepares to file a Form 10-K annual report. The report will include recent developments and forecast for 2023/24. Propanc's lead product candidate PRP targets and eradicates cancer ste..